Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

@article{Bahleda2019MulticenterPI,
  title={Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors},
  author={Rastilav Bahleda and Antoine Italiano and Cinta Hierro and Alain C Mita and Andr{\'e}s Cervantes and Nancy Chan and Mark M. Awad and Emiliano Calvo and V{\'i}ctor Moreno and Ramaswamy Govindan and Alexander I. Spira and Martha D Gonzalez and Bob Zhong and Ademi E Santiago-Walker and Italo Poggesi and Trilok V. Parekh and Hong Xie and Jeffrey R. Infante and Josep Tabernero},
  journal={Clinical Cancer Research},
  year={2019},
  volume={25},
  pages={4888 - 4897}
}
Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg… 

Figures and Tables from this paper

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
TLDR
Overall, bemarituzumab seems to be well tolerated and demonstrated single-agent activity as late-line therapy in patients with advanced-stage GEA.
Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study.
Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors.
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
  • Y. Chae, F. Hong, K. Flaherty
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2020
TLDR
Preliminary signals of activity appeared to be limited to cancers harboring FGFR activating mutations and fusions, although AZD4547 did not meet the primary end point.
An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer
TLDR
Erdafitinib, a potent and selective inhibitor of FGFRs, represents the first targeted therapy approved for the treatment of UC by virtue of a confirmed response rate of 40% in an open-label, single-armed phase II trial in molecularly selected tumors.
FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma.
The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
TLDR
The current evidence on the biological rationale, as well as preclinical and clinical development of FGFR inhibitors in iCCA are reviewed, which culminated in the US FDA-approval of pemigatinib and infigratinib.
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.
TLDR
The design, objectives and rationale for PROOF 301, a Phase III multicenter, open label, randomized trial of infigratinib in comparison to standard of care gemcitabine and cisplatin in advanced/metastatic cholangiocarcinoma with FGFR2 translocations, have the potential to define a new role for a chemotherapy-free, targeted therapy option in the front-line setting for these patients.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
TLDR
A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma
TLDR
The exploratory relationship between serum PO4 levels and efficacy/safety outcomes supported the use of pharmacodynamically guided dose titration to optimize erdafitinib’s therapeutic benefit/risk ratio.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
  • J. Tabernero, R. Bahleda, J. Soria
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
TLDR
JNJ-42756493 administered at 10 mg on a 7- days-on/7-days-off schedule achieved exposures at which clinical responses were observed, demonstrated pharmacodynamic biomarker activity, and had a manageable safety profile.
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
  • L. Nogova, L. Sequist, J. Wolf
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
TLDR
BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors
TLDR
Encouraging evidence of anti-tumor activity was seen in some patients, most notably a partial response in a patient with squamous NSCLC who had a high level FGFR gene amplification.
Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .
TLDR
Encouraging evidence of anti-tumor activity was seen in some patients, most notably a partial response in a patient with squamous NSCLC who had a high level FGFR gene amplification.
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
TLDR
The results of the current study provide a strong rationale for the clinical investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations and show rapid uptake into the lysosomal compartment of cells in culture, which is associated with prolonged inhibition of FGFR signaling.
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
TLDR
The expression pattern of these fusions in association with sensitivity to FGFR inhibitors warrant a new molecular classification of cholangiocarcinoma and suggest a new therapeutic approach to the disease.
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
TLDR
This preclinical study confirmed pharmacodynamics and identified new predictive biomarkers to FGFR inhibition with erdafitinib and supports further clinical evaluation of this compound in patients with FGFR genetic alterations.
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
TLDR
Debio 1347 is an orally available, highly selective panFGFR agonist that binds to FGFR in a novel manner to treat multiple solid tumor malignancies and shows promising results in animals and humans.
Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics
  • M. Katoh
  • Biology, Medicine
    Expert review of anticancer therapy
  • 2010
TLDR
Clinical application of small-molecule FGFR inhibitors could improve the prognosis of FGFR-driven cancer patients and prescribe broad-range tyrosine kinase inhibitors targeting FGFRs and other receptors.
...
1
2
3
4
...